New diabetes treatments can be hard to keep track of. Here we take a look at some of the newer treatments and trials for diabetes. By Angela Coffey. Being armed with the basic facts about new and potential treatments is a great way read more »

In a report entitled, Optimal prandial timing of bolus insulin in diabetes management: a review, looked at data from several studies and concluded that taking rapid-acting insulin 15–20 minutes before a meal provides significant improvements in post-meal control and was recommend by the read more »

Eli Lilly has decided to terminate its partnership with Adocia for the development of BioChaperone Lispro, an ultra-rapid insulin for diabetes. Despite results from 6 clinical studies indicating that Adocia’s ultra-rapid insulin performs better than Eli Lilly’s Humalog, the big American pharma has read more »

Novo Nordisk and Glooko have announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk’s deep knowledge of diabetes with Glooko’s digital platform and data read more »

Faster insulin The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA), has recommended marketing authorisation for Novo Nordisk Fiasp (fast-acting insulin aspart) for use in the treatment of adults with Type 1 and Type 2 diabetes. The read more »

Researchers in an international study have uncovered new genetic evidence of how the benefits of the world’s most commonly used Type 2 diabetes drug may vary between individuals. Metformin, the drug used by hundreds of millions of people with Type 2 diabetes read more »

A glucogen powder now in development by Eli Lilly to treat dangerously low blood sugar in patients with Type 1 diabetes, the goal being to replace the large needles now available (but seldom used) to inject glucogen during hypoglycaemic attacks with an read more »

Novo Nordisk has announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with Type 2 diabetes. IDegLira is a once-daily, single read more »

Nadav Kidron, CEO of Oramed Pharmaceuticals, shows an insulin pill as he poses for a photo at the company’s offices in Jerusalem September 29, 2013. REUTERS/Baz Ratner As reported by Reuters, tiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral read more »

Sanofi will focus less on diabetes monitoring devices, Chief Executive Officer Olivier Brandicourt said at the end of October (2015) after projecting disappointing sales for the company’s treatments for the disease, including two new products. Sanofi projects that diabetes sales will probably read more »